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Is Necessary  for  S tent ing?  
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8:30 
I " ~  Combined Antlplstslet Therapy WHhout 
Antic~agulation After Stent Implantation; The 
Ticlopldine Aspirin Stent Evaluation (TASTE) Study 
Jean-Marc Lablanche, Jeen-Louis Bonnet, Gilles Grollier, Nicolas Oanchin, 
Marc Bedosoa, Chdatophe Leciorcq, Alec Vahanian, Michel E. Bertrand. 
University of Lille, France 
Despite intensive anttcoagulation, subacute stent hrombosis and major hem- 
orrhagio complications remain major problems after stent implantation. 
In a pr0epactive multicenter French study, we investigated the efficacy of 
a combination of 2 antiplateiot agents, ticlopidine 500 ~ and aspidn 200 mg 
daily, without oral anticoegulation after stent implantation. Since November 
1993, 529 consecutive patients (545 vessels) were sucCeSSfUlly stented with 
conventional (non.bapadn coated) stents, for failed angioplasty (n = 112), a 
suboptimal result (n = 326), or electivaly (n == 107). We present he in-hospital 
and 4 week clinical follow-up results. 
Coronary events related or possibly related to stent thrombosis occurred in 
5.4% of patients with bailout stents, 1.8% of patients with stenla for suboptimal 
msufts. Serious blesd!irl~l-occurred in 5.4% of patients efter bailout stenting. 
Neither stont hrombosis nor seflous bleeding occurred after elective stenting. 
"liclopidine was discontinued in 1,2% of patients due to neutrepenie (0.6%) 
or rash (0.6%). Mean hospital stay decreased from 6.16 :l: 2.14 d~ys to 4.2 
4- 2.15 days during the study period. 
A combination of 2 antiplatslet agents can be employed in the vast majority 
of patients after coronary slant implantation. Supacute stent hrombosis rates 
and bleeding complications compare f'avourably ~ those reported using 
conventional therapy and the duration of hospitalisation isreduced, 
8:45 
Preliminary Results of the Must Trial. Major Clinical 
Events During the First Month 
M,C. Morioe, B. Valeix, J. Marco, J,J, Goy, P, Commeau, N, ReilarL 
V. Voudds, A. Serfs, T. Baardman. P.W Serruys I.C. V Paris Sud, France 
Intrecoronary stents am increasinly being used as an adjunct or alternative 
to balloon angioplaaty. Its major limitation is the intrinsic thromboenisity of 
metslllo stent. The French registry on coronary stenting without Go- - in  
showed a low rate of subacute thrombosis and bleeding complication with 
the association of 2 antiagmgants (Ticfopidlne and aspidn). The MUST study 
was designed to validate the concept of stenting with Ticlap~ne 250 mg 
for one month and espidn 100 rag/day for 6 months as sole post stenting 
treatment. 
In this open, pmspechva, multicentar, ~3senm,~o~d study, 21 European 
contem enrolled 2~0 patients from January tO August 1995. Patients elected 
had stable or unstable angina and were tmaled with a single 15 mm Palmaz- 
Sct~dz stont deployed on e native artory of 3 mm or moro. Only de novo 
lesions were included. 
Results: Major' adverse events dudng the fi~t month were one case of 
emergent sufgelry (0A%), 3 cases of subacute thrombosis (1.2%) and 5 M,I 
(1.S%). Seven patients (2.7%) experienced at least one major ar~'~rse event. 
In conclnsio~: com~Iry s~enting with low doses o F . B ~  is 
foasbfo and efflcte~ It ~e~-esents a low cost approach using conve~monat 
stonts, wmmut Nus guyed stent depkwmenL 
9:00 
~ l s  Ticiopidine a Necessary Component of 
Antiplatelet Regimens Following Coronary Artery 
menting 
Chfistophsr M, Goods, Khaled F. Al-Shalbi, Brian H. Negus, Ming W. Uu, 
Sanjay S. Yadav, Suresh R Jain, Larry S. Dean, Sfiram S. lyer, J. 
Michael Parks, Gary S. Roubin, University of Alabama at Birmingham, 
Birmingham, AL 
Antiplatelat therapy with Aspirin and Ticfopldine has been associated with low 
thrombosis rates following corona~ artery stenting. It is unknown if similar 
outcomes could be achieved with Aspidn alone. Between 9/94 and 8/95 342 
patients were selected to receive one of two antiplatefot regimens following 
native coronary artery stenting using the Cook stent. Patio.is were selected 
after optimal anglog~ic results were achieved, Intravasoular ultrasound 
guidance was not use~l. Group A (n = 296) were p~ents Ireated with a 
combination of Aspidn 325 mg BID and T~opidine 250 mg BID and Group B 
(n : 46) were patients treated with Aspirin 325 mg BID alone. Assignment to 
either regimen was based on physician preference. Clloieal outcomes with 
30 day follow-up am shown. 
A (n = 296) B (n = 46) P value" 
Stent hrombosis 2 (0.7%) 3 (6,6%) 0.02 
Death 1 (0.3%) 2 (4.4%) 0.05 
Bypass u ,rg?W 2 (0.7%) 0 NS 
* Fisher Exact est wflh pemada~on melhod 
Conclusion: This non-randomized, compara~ve study suggests that 
combination of Aspirin and Ticlopidine is superior to Aspirin efone in prevent- 
ing stent thrombosis. 
9:15 
Prospective Randomized THai of Antiplatslet vs. 
Anticoagulation Treatment After Intrscomnary . 
Palmaz-Schallz Stent Placement-6-Month Fol low-up 
Albert Schemig, Halmut SchOhlen, Rudolf Blasini, Adnan Kaslmti, 
Hanna Waiter, Martin Hedamitzky, Eva Zdzreann, Gert Rlohardt, 
Claus Schmitt, Eckhard Nt, Franz-Josef Neumann. I. Medizinische Klinik, 
Klin#~um rechts der Par. Technische Universi~t Munich, Germany 
Recent studies have advocated the feasibility of antiplatelet therapy alone to 
prevent hrombotic occlusions after coronary stellt placement. The goal of our 
randomized Vial is to compare anttcoagula6nn therupy with antipfotelat ther- 
apy after su,:,~-s=,~ul Palmaz~T.~chatz s ent placement. The poSUntswenlion 
armT(oagulation protocol consists of aspirin (100 mg bid) + phenlxocoumon 
with i.v.-hepadn until the target INR of 3.5 is reached, The an~protsco l  
consists of aspidn (10~ mg bid) + ticfopidina (250 mg bid). Phenprocoumon 
and ticlupidina m both given for four weeks. Randomization started October 
1, 1994 to continue for one year. Analysis will include defined endpolots 
of cardiac (death, Infection, occlusion of the stentsd vessel, repeat PTCA, 
CABG), non cardiac events (groin complications or bleeding requiring surgery 
or transfusion, or impaldng organ function) and angiegmphlo utcome. By 
August 31,1995 473 patients hed been randondzed. 
Analysis of the two treatment ~ for clinical events during a 30 day 
and 6 month follow Up period and an~hlc  6 month outcome will be 
present~. 
9:30 
In-Hospital and l~ lonth  Clinical Results Of~n t t Intsmattonal Study Testing the Concept o! IVU~. 
Peter de Jasgere, Harald Mudra. Ymon Nmagor, Hans Flgufl~ lan Penn, 
Seine Deus~ Am~o Barren(, Ct~st~n Ha .~ ~ the Mu'~c S~Y 
,~st~fo~.  Roa~e~am, The ~ 
A ~e ~er  ~ de~n~ra~d th= ~ ant~a~on can 
safoly be omitlad alter i~-a,~,~-ona,'y ~ provided ~ stent expan- 
sk~ ~ olr,~-~ ~ ~ h~h presume bano~s ~d WUS gu~anoe. Th~ 
c.~-.:~t is vandated In a rnsgk:ent~ approach by using an open. ProSPe'> 
tire, ~- -~:  study (MUS~ Study). For th~ ~ ,  the h-~;-,~¢e of 
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Table 1 
Evenl 
Death 
Q.AMI 
non-Q AMI 
CABG 
rePTCA 
SAT 
In-hospital 
Total Ranking 
O 0 
0 0 
4 (2.5%) 4 
0 0 
1 (0.6%) 0 
1 (0.6%) o 
Discharge-- t mertth 
Total Ranking 
0 0 
1 (0.6%) 1 
0 0 
1 (0,6%) 1 
2 (1,3%) 2 
0 0 
slant thrombosis (SAT) and ~rdiac events were assessed in 160 pts, All pts 
received a single Palmaz-Sthatz sfont because of stable angina and u de 
nero coronary lesion. The protoCOl outlines that pts meeting the IVUS criteria 
of optimal stent expansion only receive ASA > 100 rag, while those not 
meeting the criteria receive ASA, oral and iv ant+coagulation after alenting. 
83% of the pts received ASA (of whom 17% should have been treated with 
anticoagulants ~ protocol violation) and 17=/= received systemio ant+coagu- 
lation. A total count of events and ranking according to the worst category 
analysis is shown in Table 1, 
This muiticentri¢ study confirms that stents can indeed be safely implanted 
without he institution of systemic anticoegulation. 
9:45 
~ - ~  Integrelin for Coronary Artery Stenting Emergency 
James P, Zidar, Kevin R. Kruse, Mark C. Thel, Dean Kereiakas, Joseph 
B, Muhlestsin, Chades J. Davidson, Paul S, Teirstein, Alan Tenaglia, Steven 
J. Yakubov, Jeffrey J. Popma, Jean-Francois Tanguay, Michael M. Kilt, Todd 
J. Lorenz, James E. Tcheng, A, Michael Lincoif, Robert M. Calliif, Eric 
J. Topoi for the IMPACT II Investigators. Duke University, Ourham, NC 
TO assess the potential benefit of GP lib/Ilia inhlbitors with COrOnary slant- 
ing, we studied 160 patients who required alents for true/threatened closure 
in the IMPACT it trial. In this trial of 4010 patients, no stents were placed 
eleclivaly by protocol design. A composite end point of death, MI, urgent 
repeat intervention or CABG was compared between the slant patients in 
the placebo arm vs. ptS randomized to one of two Integrelin doses. Baseline 
cheracleristi~ were similar betweer~ tho stent and n0n.stented groups. En- 
rollment status was characterized as high risk in 45% of patients in the stent 
group vs 41% in the non-slant group. Most (87%) slant patients received a 
Cook stent and were discharged on warfarin. 
Endpoints at 30 days! Integrefln (  = 101 ) Placebo (n = 59) p 
composite ndpeint 31% 49%. 0,021 
MI 16% 32% 0.017 
Urgent CABG ?% 8%,* 0,723 
Urgsnt repeal intervention G% 8% 0.546 
Death 2% 1.7% 0.897 
Major bleeding complication 21% 21% 0.956 
Conclusions: The high event rates in both groups reflect the "true bailout" 
indication for stsnting, Integrelin improves 30 day clinical outcome by reduc- 
ing the risk of MI in patients requiring slants after failed PTCA, without an 
increase in bleeding. This suggests the importance of GP lib/Ilia inhibition in 
coronary slanting. 
Ang lop laaty  and Restenos is :  Ro le  o f  Stents  
Tuesday, March 26, 1996, 8:30 a .m. -10:00 a.m. 
Orange County  Convention Center, Room 314 
8:30 
~ l s  Them Need for Intravsscular Ultrasound After 
High-Pressure Dilatations of  Palmaz-Schatz Stente 
Kathioen M. Allen, Caned Undemlr. Alexander 8haknovich. Jeffrey Moses. 
Janet StE!n, Edward Kreps. Lsnox Hill Hospital, New York, NY 
Use of intrevescular ullre, sound (IVU,~) in conjunction with angiegraphio as- 
sessment of Palmaz-Schalz slants (PSSs) provided the rationale for routine 
post.deployment high pressure dilatation (HPD) of P,,~Ss. To address the 
question of whether outine NPD obviates the need for IVUS, we reviewed 
IVUS and quarditatlve angi0graphic (QCA) data in 91 pts with 96 lesions. 
HPO was performed in all pts (mean i:r(essure 16.7 4-1.6 ATM; range 14,-20 
ATM) with 1-1.1 balloon; artery ratio, Further imprevements were neces- 
ss~ In 4,5/96 vessels after post-HPD IVUS secondary to suboptimal stent 
geometry (32), I~Otn~ing tissue (5), and dissection/eddifional sten0sas (8). 
8 vessels requira~, additional PSSs and 37 further HPDs (17 with ~ same 
JACC Febm.~ry 1996 
and 2G with a ;arger balloon). IVUS (rt = 45) ~r~J ~A (n =* 30) wo~ repasted 
after each HPD. 
Pest HPD Final p value 
QGA MLO (ram) 2.66 ± 0.54 2.92 :E 0.50 0,055 
QCA stenoais % 5.95 ,.I- 8,86 -1.82,9.98 0,0007 
IVU8 MLD (ram) 2.81:1:0A1 3.10 + 0.39 0,001 
IVUS stenosis % 19.6 ± 9.2 9.85 :h 12,2 0,0002 
CSA (mm2) 7.5 ± 1.SS 8.97 + 2.03 0,001 
.Symmetry , 0.aS + 0.07 0.gO :~ 0.062 0,21 
Conclusions: In nearly half of P,~,Ss, IVUS folfowing HPD identified sub- 
optimal results which were improved with further intervention, A prospective 
randomized trial will be necessary to verify if this strategy alters clinical 
outcome. 
8:45 
~ Inlluence of  Size on the Late Restenotic Vessel 
Process After Successful  Stent Implantation 
Naeya Hamasaki, Hldeyuki Nasaka, Takeshi Kimure, Himyoshi Yok0i, 
Takashi Tamura, Yashihiro Sawada. Masakiyo Nobuysshi. Kitakyushu, 
Kokura Memorial Hospital, Japan 
The purpose of the present study was to investigate the influence of vessel 
size on late angiogrephic outcome after successful single stent placement, 
The study population compdsed 547 consecutive lesions implanted native 
artedes [Palmatz*$ohalz 436, Gianturco-Roubin 50, Cottlis. 61] and satis- 
factodc angiogrephic analysis before and after slanting and at 3 or 6 months 
follow-up (FUP) from a single center (Feb. 1990-Feb. 1995). 
Vassal size < 3.0 mm 3,0,-3.5 mrn > 3,5 mm 
Acute gain 1.86 + 0.67 2,05 + 0.44 2.22 :~ 0,55 P - 0.0001 
Late loss  0.89+0.67 0.97:1:0.64 0,81 :~0,65 P,= 0,56 
MLD FLIP 1.76±0,63 2.02:b 0,6 2,40~0.63 P ,~ 0,0001 
.I Re la t iVe  loss  i 
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Vessel size was found to be exert a significant positive influence on MLD 
at FUP and an equally negative elfect on loss by muifivadable analysis (p < 
0.001). The relative gain/loss relationships within the lesion groups showed 
that it does not vary with vessel size, In conclusion, vessel size ifse~11 does not 
influence the restenosls process, which appears to be determined mainly by 
the degree of luminal increase achieved at slanting, regardless of the veSsel 
size. 
9 :00 
~ Dlatrlbutlon of  Tissue Growth In Palmaz-Schatz 
Stents: Ina l~t ts  F rom a Serial Intravascular 
Ultrasoun¢l'~fudy 
Ralner Hoffman, Gary S. Mlntz, Jeffrey J. Popma, Augusto D. Pichard, 
Lowell R Seller, Kenneth M. Kent, Roxana Mehreo, Martin B. Leon. 
Washington HospitaI Center, Washington, DC 
Previous studies have suggested that Instant restenosis is (1) due to inttmal 
hypelplasia and (2) occurs most frequently at the central articulation (CA) of 
Palmaz-Schatz slants. To understa~ this process, we compared Sedal {post- 
intervention and follow-up (F/U 5.4 4- 3.8 rues)} Intravasculm ultrasound 
studies in 104 slants implanted into 49 native and 39 SVG lesions, Lumerl 
and slant areas (in mm z) were measured; plaque (slant-lumen) area, late 
lumen toss (&lumen area) and tissue growth (&plaque area) were calculated 
for the edges, body, and CA of all slants: 
Edges., Body CA p(ANOVA) 
Post sterd area 10.t +4.1 9.5 • 3.6 9.6 :E 4.0 0.0005 
RU slant area 9.9+1:4.1 9.8 ~3.8 9,4+9.8 0.01 
Post lumen area  10.0+4.0 9.5±3.6 9.1:t:3.9 <0.000t 
F/U lumen area 7.1 :E3.9 8.5:1:3.6 6.0+4.1 <0.CO0t 
Post plaque area 0.0 + 0.1 0.0.4- 0.0 0.5 + 1.1 <0.0001 
F/U ¢A~ue ares 2.8:1:2.0 3.0 :I: 2.0 3,4 + 2.6 <0.0001 
Late lumen lo=~ 2.8:1:1.6 3.0:1:2.0 3,1 +25 NS 
T~s~gmwth 2.6 + 1.9 2.9 ± 2.0 2,8 + 2.5 NS 
The kntten 8t the cat,rat artJctdatton Is smaJler than at the bady or ¢:~v~ e! 
the rant besause of a s,g~y sma,er stem a~ea nd s ~  Wokmse 
